The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery

HaEmek Medical Center, Israel

Status and phase

Withdrawn

Phase 4

Conditions

Femur Surgery

Treatments

Drug: control grup: without Tranexamic Acid (TXA) treatment.

Drug: Tranexamic Acid (TXA) treatment

Study type

Interventional

Funder types

Other

Identifiers

104-12-EMC

Details and patient eligibility

About

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients over 60, who came to the orthopedic department for proximal femur fracture surgery
Sound judgment

Exclusion criteria

Known hypersensitivity to Tranexamic Acid or component solution provided
Subarachnoid hemorrhage
Acquired color blindness
Myocardial infarction in 12 months before admission
Unstable angina
Known clotting disorders (Thromboembolic disease in the past, elongated PT and PTT, hypercoagulability),
Kidney or liver failure
Another situation prostate resection , pathologic fractures according to anamnesis or by imaging
Oncology patients
Patients on anticoagulation
Patients undergoing vascular intervention ( coronary or peripheral ), which was inserted Supporter requires a Dual antiplatelet therapy